A Phase IIa Multicenter, Open-label, 12-week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype
Latest Information Update: 17 Dec 2025
At a glance
- Drugs Alogabat (Primary)
- Indications Angelman syndrome
- Focus Adverse reactions; Pharmacokinetics
- Acronyms Aldebaran
- Sponsors Roche
Most Recent Events
- 04 Dec 2025 Status changed from active, no longer recruiting to completed.
- 04 Nov 2025 Planned End Date changed from 4 Dec 2025 to 2 Dec 2025.
- 04 Nov 2025 Planned primary completion date changed from 4 Dec 2025 to 2 Dec 2025.